Validation of the OHI Index for Hematologic Malignancies
A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index
This study is testing a new index to see if it can help doctors better understand and predict outcomes for patients with blood cancers who might develop a serious condition called HLH.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Meir Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Kfar Saba and 1 other locations) |
| Trial ID | NCT05882175 on ClinicalTrials.gov |
What this trial studies
This study aims to validate the Optimized HLH Inflammatory (OHI) index in patients with hematologic malignancies who may develop hemophagocytic lymphohistiocytosis (HLH). It will enroll patients with new or transformed hematologic malignancies and follow them to assess their survival and prognosis over one year. The OHI index is based on specific biomarkers, including elevated levels of soluble CD25 and ferritin, which may help in diagnosing and predicting outcomes for patients with this serious condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with newly diagnosed or transformed hematologic malignancies.
Not a fit: Patients who have received recent treatment for their hematologic malignancy within the last month may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve diagnostic accuracy and prognostic assessment for patients with HLH associated with hematologic malignancies.
How similar studies have performed: While the OHI index is a novel approach, similar studies have shown the importance of biomarkers in improving outcomes for patients with HLH.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with hematologic malignancies * At least 18 years old Exclusion Criteria: * Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)
Where this trial is running
Kfar Saba and 1 other locations
- Meir Medical Center — Kfar Saba, Israel (Recruiting)
- Rabin Medical Center — Petah Tikva, Israel (Recruiting)
Study contacts
- Principal investigator: Adi Zoref-Lorenz — Meir Medical Center
- Study coordinator: Adi Zoref Lorenz, MD
- Email: adi.zoref.lorenz@cchmc.org
- Phone: 513 6525610
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.